Nurix Therapeutics, Inc. (NASDAQ:NRIX) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$250M raised · US$10.21 a share · J.P. Morgan Securities LLC +4 Dealers: J.P. Morgan Securities LLC (co-lead), Jefferies LLC (co-lead), Stifel, Nicolaus & Company, Incorporated (co-lead), Oppenheimer & Co. Inc., Robert W. Baird & Co. Incorporated Buyers: General Atlantic; Redmile Group; Braidwell LP; Deep Track Capital; Perceptive Advisors; Trails Edge Capital Partners; Vestal Point Capital Use of proceeds: Clinical development of drug candidates incl. bexobrutideg in CLL and autoimmune indications, R&D to expand pipeline, working capital and general purposes | Oct 27, 2025 |